Matinas BioPharma Holdings (MTNB) Other Non-Current Liabilities (2015 - 2025)
Matinas BioPharma Holdings (MTNB) reported Other Non-Current Liabilities of $1.3 million for Q1 2025, up 1414.77% quarter-over-quarter from $88000.0 in Q4 2022.
Matinas BioPharma Holdings (MTNB) Other Non-Current Liabilities (2015 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 7 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q1 2025.
- Other Non-Current Liabilities for Q1 2025 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $1.3 million (changed N/A YoY), and the FY2022 annual result was $88000.0, down 90.21% from the prior year.
- Other Non-Current Liabilities grew to $1.3 million in Q1 2025 per MTNB's latest filing, from $88000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.3 million in Q1 2025 and troughed at $88000.0 in Q4 2022.
- A 3-year average of $642888.9 and a median of $669000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 337.25% in 2022 and fell as far as 90.21% in 2022.
- A 3-year view of Other Non-Current Liabilities shows it stood at $899000.0 in 2021, then plunged by 90.21% to $88000.0 in 2022, then jumped by 1414.77% to $1.3 million in 2025.
- Business Quant data shows MTNB's Other Non-Current Liabilities at $1.3 million in Q1 2025, $88000.0 in Q4 2022, and $194000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.33 Mn |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | 194,000.00 |
| Jun 30, 2022 | 444,000.00 |
| Mar 31, 2022 | 669,000.00 |
| Dec 31, 2021 | 899,000.00 |
| Sep 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 807,000.00 |
| Mar 31, 2021 | 153,000.00 |
| Dec 31, 2020 | 899,000.00 |
| Jun 30, 2018 | 587,143.00 |
| Mar 31, 2018 | 589,143.00 |
| Dec 31, 2017 | 601,143.00 |
| Sep 30, 2017 | 603,143.00 |
| Sep 30, 2015 | 781,729.00 |